HALOZYME THERAPEUTICS, INC. Quarterly Operating Income (Loss) in USD from Q2 2010 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Halozyme Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q2 2010 to Q3 2024.
  • Halozyme Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was $163M, a 84.9% increase year-over-year.
  • Halozyme Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was $477M, a 53.4% increase year-over-year.
  • Halozyme Therapeutics, Inc. annual Operating Income (Loss) for 2023 was $338M, a 26.2% increase from 2022.
  • Halozyme Therapeutics, Inc. annual Operating Income (Loss) for 2022 was $268M, a 3.03% decline from 2021.
  • Halozyme Therapeutics, Inc. annual Operating Income (Loss) for 2021 was $276M, a 91.3% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $477M $163M +$74.9M +84.9% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-31
Q2 2024 $402M $117M +$22.8M +24.1% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-06
Q1 2024 $379M $95.5M +$41.7M +77.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $338M $101M +$26.5M +35.6% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 $311M $88.3M +$4.99M +5.99% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-31
Q2 2023 $306M $94.5M +$60.4M +177% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-06
Q1 2023 $246M $53.8M -$21.9M -28.9% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $268M $74.5M +$18M +31.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 $250M $83.3M +$7.71M +10.2% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $242M $34.1M -$59M -63.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $301M $75.7M +$24.9M +49.1% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $276M $56.5M -$21.1M -27.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 $297M $75.6M +$35.3M +87.6% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 $262M $93M +$63.5M +215% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $198M $50.7M +$54M Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $144M $77.6M +$110M Oct 1, 2020 Dec 31, 2020 10-K 2023-02-21
Q3 2020 $34.6M $40.3M +$64.8M Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-02
Q2 2020 -$30.3M $29.6M +$43.5M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$73.8M -$3.22M -$6.19M -209% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 -$67.6M -$32.1M -$32M -45058% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-22
Q3 2019 -$35.6M -$24.5M +$937K +3.68% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-02
Q2 2019 -$36.6M -$14M +$6.1M +30.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 -$42.7M $2.97M +$26.7M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$69.3M -$71K -$126M -100% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-23
Q3 2018 $56.7M -$25.5M -$33.6M -415% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $90.2M -$20.1M +$5.41M +21.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-06
Q1 2018 $84.8M -$23.7M +$3.81M +13.9% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $81M $126M +$149M Oct 1, 2017 Dec 31, 2017 10-K 2020-02-24
Q3 2017 -$67.5M $8.08M +$30.8M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-06
Q2 2017 -$98.3M -$25.5M -$3.76M -17.3% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q1 2017 -$94.6M -$27.5M -$11.4M -70.2% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10
Q4 2016 -$83.2M -$22.6M -$28M -513% Oct 1, 2016 Dec 31, 2016 10-K 2019-02-21
Q3 2016 -$55.2M -$22.7M +$494K +2.13% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-07
Q2 2016 -$55.7M -$21.7M -$26M -613% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-08
Q1 2016 -$29.7M -$16.2M -$2.26M -16.2% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q4 2015 -$27.5M $5.47M +$9.32M Oct 1, 2015 Dec 31, 2015 10-K 2018-02-20
Q3 2015 -$36.8M -$23.2M -$4.21M -22.1% Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-07
Q2 2015 -$32.6M $4.23M +$19.2M Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
Q1 2015 -$51.7M -$13.9M +$11.3M +44.8% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-09
Q4 2014 -$63M -$3.85M +$17.5M +81.9% Oct 1, 2014 Dec 31, 2014 10-K 2017-02-28
Q3 2014 -$80.5M -$19M -$532K -2.88% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-09
Q2 2014 -$80M -$14.9M +$7.18M +32.5% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-10
Q1 2014 -$87.2M -$25.2M -$6.72M -36.4% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-11
Q4 2013 -$80.4M -$21.3M -$16.9M -384% Oct 1, 2013 Dec 31, 2013 10-K 2016-02-29
Q3 2013 -$63.5M -$18.5M +$1.54M +7.67% Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-10
Q2 2013 -$65.1M -$22.1M -$8.07M -57.5% Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-11
Q1 2013 -$57M -$18.5M -$3.35M -22.2% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12
Q4 2012 -$53.6M -$4.41M +$14M +76.1% Oct 1, 2012 Dec 31, 2012 10-K 2015-03-02
Q3 2012 -$67.6M -$20M -$25.2M -489% Jul 1, 2012 Sep 30, 2012 10-Q 2013-11-08
Q2 2012 -$42.5M -$14M -$17.1M -554% Apr 1, 2012 Jun 30, 2012 10-Q 2013-08-07
Q1 2012 -$25.3M -$15.1M -$5.48M -56.7% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-08
Q4 2011 -$19.8M -$18.4M Oct 1, 2011 Dec 31, 2011 10-K 2014-02-28
Q3 2011 $5.15M +$17.6M Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-08
Q2 2011 $3.1M +$15.2M Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-09
Q1 2011 -$9.66M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-07
Q3 2010 -$12.4M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-08
Q2 2010 -$12.2M Apr 1, 2010 Jun 30, 2010 10-Q 2011-08-05
* An asterisk sign (*) next to the value indicates that the value is likely invalid.